You are here: Home » PTI Stories » National » News
Business Standard

Ashwagandha can be effective COVID-19 preventive drug, finds research by IIT Delhi and Japan's AIST

Topics
Health Medical Pharma

Press Trust of India  |  New Delhi 

Ayurvedic herb Ashwagandha can be an effective therapeutic and preventive drug against the COVID-19 infection, a collaborative research by IIT-Delhi and Japan's National Institute of Advanced Industrial Science and Technology (AIST) has found.

The natural compounds from Ashwagandha and Propolis have the potential to be an effective novel coronavirus preventive drug, according to the research team.

"The researchers targeted the main SARS-CoV-2's enzyme for splitting proteins, known as the main protease (Mpro), that plays a key role in mediating viral replication. This is an attractive drug target for this virus, and as humans don't naturally have this enzyme, compounds that target Mpro are likely to have low toxicity," said D Sundar, head of the Delhi Indian Institute of Technology's Biotechnology department.

The findings may not only connect to save time and cost required for screening for anti-COVID-19 drugs, but may also offer some preventive and therapeutic value for the management of fatal COVID-19 pandemic, and hence, warrant prioritized validation in the laboratory and clinical tests," he said.

The drug's development may take some time, and in the current scenario, these natural resources -- Ashwagandha and Propolis -- can offer some preventive or even therapeutic value, according to Sundar.

He said that although these are easily available and affordable, one has to be cautious about the content of bioactive ingredients. CAPE, while is a major component of propolis, its amount and stability are critical factors that could be managed by generating its complex with cyclodextrins.

Withanone, on the other hand, varies with geography, parts and size of the Ashwagandha plant. So, in order to acquire or appreciate particular effects, we must use the right and quality-controlled resource and extracts," Sundar said.

The government has also initiated a study on whether Ashwagandha can be an alternative to anti-malarial drug Hydroxychloroquine (HCQ) as a potential COVID-19 preventive.

The study is being carried out by a group of scientists and researchers from the Ministry of AYUSH, Ministry of Health and Family Welfare, University Grants Commission (UGC) and Indian Council of Medical Research (ICMR).

"While new line of drug and vaccine development have been initiated worldwide, in the current scenario of high infected numbers, severity of the disease and high morbidity, repurposing of the existing drugs are heavily explored by recruiting integrative genomics and bioinformatics research tools, Sundar said.

"While well-trusted reputation of Ashwagandha as an immunity enhancer forms a basis of the recent initiative of the Indian government in forming an Interdisciplinary Task Force to launch its clinical research studies related to SARS-CoV-2 and the COVID-19 disease, the current research report of this team provide hints on its direct anti-viral activities," he said.

The novel coronavirus has claimed over three lakh lives with over 48 lakh people infected across the globe. In India, 3,029 people have died due to the disease and 91,169 have been infected.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, May 18 2020. 18:40 IST
RECOMMENDED FOR YOU